Thalys Medical Technology Group Inc banner

Thalys Medical Technology Group Inc
SSE:603716

Watchlist Manager
Thalys Medical Technology Group Inc Logo
Thalys Medical Technology Group Inc
SSE:603716
Watchlist
Price: 22.72 CNY -3.36% Market Closed
Market Cap: ¥4.8B

Multiples-Based Value

The Multiples-Based Value of one Thalys Medical Technology Group Inc stock under the Base Case scenario is hidden CNY. Compared to the current market price of 22.72 CNY, Thalys Medical Technology Group Inc is hidden .

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Thalys Medical Technology Group Inc Multiples-Based Value
LOCKED
Unlock
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Thalys Medical Technology Group Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Thalys Medical Technology Group Inc
SSE:603716
4.8B CNY 3.8 -19.9 -44.7 -44.7
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
375.5B USD 6.1 89.7 14.8 20.6
US
Amgen Inc
NASDAQ:AMGN
191.7B USD 5.2 24.8 14.4 14.4
US
Gilead Sciences Inc
NASDAQ:GILD
176.3B USD 6 20.7 12.9 16
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
113.5B USD 9.5 28.7 21.6 22.5
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.2B USD 5.7 18 13.5 15.4
NL
argenx SE
XBRU:ARGX
41.9B EUR 11.8 37.9 40.9 41.8
AU
CSL Ltd
ASX:CSL
67.6B AUD 3 32.7 11 13.9
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
P/S Multiple
Revenue Growth P/S to Growth
CN
Thalys Medical Technology Group Inc
SSE:603716
Average P/S: 3 063 003.2
3.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.2
3%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
6
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.7
10%
0.6
NL
argenx SE
XBRU:ARGX
11.8
28%
0.4
AU
CSL Ltd
ASX:CSL
3
4%
0.7
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
P/E Multiple
Earnings Growth PEG
CN
Thalys Medical Technology Group Inc
SSE:603716
Average P/E: 36.1
Negative Multiple: -19.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
89.7
97%
0.9
US
Amgen Inc
NASDAQ:AMGN
24.8
20%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
20.7
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.7
17%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
13%
1.4
NL
argenx SE
XBRU:ARGX
37.9
32%
1.2
AU
CSL Ltd
ASX:CSL
32.7
10%
3.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Thalys Medical Technology Group Inc
SSE:603716
Average EV/EBITDA: 18.4
Negative Multiple: -44.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
14.8
12%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
10%
1.4
US
Gilead Sciences Inc
NASDAQ:GILD
12.9
9%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.6
16%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
18%
0.7
NL
argenx SE
XBRU:ARGX
40.9
50%
0.8
AU
CSL Ltd
ASX:CSL
11
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Thalys Medical Technology Group Inc
SSE:603716
Average EV/EBIT: 20.6
Negative Multiple: -44.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
20.6
23%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.4
3%
4.8
US
Gilead Sciences Inc
NASDAQ:GILD
16
13%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.5
17%
1.3
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.4
23%
0.7
NL
argenx SE
XBRU:ARGX
41.8
51%
0.8
AU
CSL Ltd
ASX:CSL
13.9
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett